CL2009000889A1 - Compuestos derivados de 2-oxo-2,5-dihidro pirrol propionamida, activadores de glucoquinasa; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compestos; y su uso en el tratamiento de diabetes mellitus. - Google Patents
Compuestos derivados de 2-oxo-2,5-dihidro pirrol propionamida, activadores de glucoquinasa; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compestos; y su uso en el tratamiento de diabetes mellitus.Info
- Publication number
- CL2009000889A1 CL2009000889A1 CL2009000889A CL2009000889A CL2009000889A1 CL 2009000889 A1 CL2009000889 A1 CL 2009000889A1 CL 2009000889 A CL2009000889 A CL 2009000889A CL 2009000889 A CL2009000889 A CL 2009000889A CL 2009000889 A1 CL2009000889 A1 CL 2009000889A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- oxo
- treatment
- pharmaceutical composition
- propionamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Compuestos derivados de 2-oxo-2,5-dihidro-pirrol-propionamida sustituidos, procedimiento de preparación, composición farmacéutica, útil para el tratamiento de la diabetes mellitus.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4537008P | 2008-04-16 | 2008-04-16 | |
US14576109P | 2009-01-20 | 2009-01-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2009000889A1 true CL2009000889A1 (es) | 2010-07-19 |
Family
ID=40785354
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2009000889A CL2009000889A1 (es) | 2008-04-16 | 2009-04-14 | Compuestos derivados de 2-oxo-2,5-dihidro pirrol propionamida, activadores de glucoquinasa; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compestos; y su uso en el tratamiento de diabetes mellitus. |
Country Status (25)
Country | Link |
---|---|
US (1) | US7741327B2 (es) |
EP (1) | EP2274297B1 (es) |
JP (1) | JP5518838B2 (es) |
KR (1) | KR101259249B1 (es) |
CN (1) | CN102007118B (es) |
AR (1) | AR071474A1 (es) |
AT (1) | ATE557017T1 (es) |
AU (1) | AU2009237794B2 (es) |
BR (1) | BRPI0911035B8 (es) |
CA (1) | CA2720524C (es) |
CL (1) | CL2009000889A1 (es) |
CY (1) | CY1112921T1 (es) |
DK (1) | DK2274297T3 (es) |
ES (1) | ES2386192T3 (es) |
HR (1) | HRP20120589T1 (es) |
IL (1) | IL207503A (es) |
MX (1) | MX2010011226A (es) |
PE (1) | PE20091842A1 (es) |
PL (1) | PL2274297T3 (es) |
PT (1) | PT2274297E (es) |
RU (1) | RU2010146384A (es) |
SI (1) | SI2274297T1 (es) |
TW (1) | TW200944519A (es) |
WO (1) | WO2009127546A1 (es) |
ZA (1) | ZA201006159B (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110021570A1 (en) * | 2009-07-23 | 2011-01-27 | Nancy-Ellen Haynes | Pyridone glucokinase activators |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
CN102959076B (zh) | 2010-03-31 | 2015-09-16 | 斯克里普斯研究所 | 重编程细胞 |
US8178689B2 (en) * | 2010-06-17 | 2012-05-15 | Hoffman-La Roche Inc. | Tricyclic compounds |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
AR082590A1 (es) | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
US20120142705A1 (en) * | 2010-12-06 | 2012-06-07 | Robert Francis Kester | Isatin and oxindole compounds |
US8470866B2 (en) * | 2011-05-03 | 2013-06-25 | Hoffmann-La Roche Inc. | Isoindolinone derivatives |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
NZ709362A (en) * | 2012-12-25 | 2019-07-26 | Hua Medicine | Process for the preparation of 1-([1,3]dioxolan-4-ylmethyl)-1h-pyrazol-3-ylamine |
CN109715637B (zh) | 2016-07-22 | 2022-04-05 | 百时美施贵宝公司 | 葡萄糖激酶激活剂及其使用方法 |
AU2017376544C1 (en) * | 2016-12-15 | 2021-06-24 | Hua Medicine (Shanghai) Ltd. | Oral preparation of glucokinase activator and preparation method therefor |
EA201991548A1 (ru) | 2016-12-22 | 2020-01-17 | Байер Кропсайенс Акциенгезельшафт | Замещенные гетероарилпирролоны, а также их соли, и их применение в качестве гербицидных действующих веществ |
BR112019012822A2 (pt) | 2016-12-22 | 2019-11-26 | Bayer Ag | 1,2,4-tiadiazolilpirrolonas e 1,2,4-tiadiazolil-hidantoínas e sais das mesmas e uso das mesmas como herbicidas |
BR112020012166A2 (pt) | 2017-12-19 | 2020-11-24 | Bayer Aktiengesellschaft | n-heterociclil- e n-heteroaril-tetra-hidropirimidinonas substituídas e os sais das mesmas, e o uso das mesmas como substâncias ativas herbicidas |
EP3811939A4 (en) * | 2018-05-31 | 2022-05-25 | Hua Medicine (Shanghai) Ltd. | PHARMACEUTICAL COMBINATION, COMPOSITION AND FORMULATION CONTAINING A GLUCOSIDASE ACTIVATOR AND A &X3B1;-GLUCOSIDASE INHIBITOR, METHODS OF PREPARING THEM AND USES THEREOF |
US11813274B2 (en) | 2020-04-22 | 2023-11-14 | Hua Medicine (Shanghai) Ltd. | Treating untreated or treatment-resistant diabetes with glucokinase activator and sodium-glucose cotransporter-2 inhibitor |
AU2020443475A1 (en) * | 2020-04-22 | 2022-11-17 | Hua Medicine (Shanghai) Ltd. | Treating untreated or treatment-resistant diabetes with glucokinase activator and sodium-glucose cotransporter-2 inhibitor |
WO2022144021A1 (zh) * | 2021-01-04 | 2022-07-07 | 华领医药技术(上海)有限公司 | Dorzagliatin和胰高血糖素样肽-1类似物的药物组合物 |
CN113527265B9 (zh) * | 2021-02-02 | 2022-07-19 | 湖南南新制药股份有限公司 | 一种氘代吡咯烷酮衍生物、药物组合物及其用途 |
CN113750100B (zh) * | 2021-08-31 | 2022-12-30 | 海南中济医药科技有限公司 | 一种含有多扎格列艾汀与西格列汀的药物组合物及其制备方法 |
AR127064A1 (es) | 2021-09-15 | 2023-12-13 | Hua Medicine Shanghai Ltd | Prodroga de derivados de pirrolidona como activador de glucoquinasa |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE842346C (de) | 1950-10-14 | 1952-06-26 | Joachim Dipl-Chem Dr Goerdeler | Verfahren zur Darstellung von 5-Amino-1, 2, 4-thiodiazolen |
NO844147L (no) | 1983-10-18 | 1985-04-19 | Du Pont | Nye 8-substituerte pyrazolopentathiepiner og beslektede forbindelser og deres anvendelse som fungicider og som svovelsensitiviseringsmidler i fotografiske emulsjoner |
JPS6284064A (ja) | 1985-10-09 | 1987-04-17 | Shionogi & Co Ltd | 3−パ−フルオロアルキル−5−ヒドロキシイソオキサゾ−ル類 |
CH668422A5 (de) | 1986-06-26 | 1988-12-30 | Lonza Ag | 4-benzyloxy-3-pyrrolin-2-on, dessen herstellung und verwendung zur synthese von tetramsaeure. |
GB9103454D0 (en) | 1991-02-19 | 1991-04-03 | Pfizer Ltd | Therapeutic agents |
IL116507A (en) | 1991-11-13 | 1997-08-14 | Schering Ag | Pyrazole derivatives |
US5498190A (en) | 1994-06-27 | 1996-03-12 | Handsontoys, Inc. | Flexible foam construction toy and method of manufacturing same |
JPH08151386A (ja) | 1994-09-27 | 1996-06-11 | Takeda Chem Ind Ltd | 複素環エチルチオセフェム化合物、その製造法および抗菌組成物 |
US6114541A (en) | 1997-03-10 | 2000-09-05 | Hoffmann-La Roche Inc. | Method for the preparation of α-Bromo-Lactam derivatives |
CN1198838C (zh) | 1998-04-30 | 2005-04-27 | 阿格罗尼制药公司 | 抗小rna病毒化合物及其制备方法和用途 |
GB9812523D0 (en) | 1998-06-10 | 1998-08-05 | Angeletti P Ist Richerche Bio | Peptide inhibitors of hepatitis c virus ns3 protease |
KR100455635B1 (ko) | 1999-03-29 | 2004-11-06 | 에프. 호프만-라 로슈 아게 | 글루코키나제 활성화제 |
US6610846B1 (en) | 1999-03-29 | 2003-08-26 | Hoffman-La Roche Inc. | Heteroaromatic glucokinase activators |
RU2242469C2 (ru) * | 1999-03-29 | 2004-12-20 | Ф.Хоффманн-Ля Рош Аг | Активаторы глюкокиназы |
IL147395A0 (en) | 1999-07-15 | 2002-08-14 | Pharmacopeia Inc | Bradykinin b1 receptor antagonists |
GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
ES2233660T3 (es) | 2000-05-03 | 2005-06-16 | F. Hoffmann-La Roche Ag | Activadores de glucokinasa alquinil fenil heteroaromaticos. |
EP1283830B1 (en) | 2000-05-08 | 2008-06-18 | F. Hoffmann-La Roche Ag | Para-amine substituted phenylamide glucokinase activators |
MXPA02010796A (es) | 2000-05-08 | 2003-03-27 | Hoffmann La Roche | Fenilacetamidas sustituidas y sus usos como activadores de glucocinasa. |
CA2429642C (en) | 2000-12-06 | 2007-11-20 | F. Hoffmann-La Roche Ag | Fused heteroaromatic glucokinase activators |
GB0112834D0 (en) | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
RS93604A (en) * | 2002-04-26 | 2007-02-05 | F. Hoffmann-La Roche Ag., | Substituted phenylacetamides and their use as glucokinase activators |
KR101116627B1 (ko) | 2002-06-27 | 2012-10-09 | 노보 노르디스크 에이/에스 | 치료제로서 아릴 카르보닐 유도체 |
EP1549626A1 (en) | 2002-10-03 | 2005-07-06 | Novartis AG | Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes |
WO2004033462A2 (en) | 2002-10-09 | 2004-04-22 | The Board Of Trustees Of The University Of Illinois | METHOD OF PREPARING (3R, 3aS, 6aR) -3- HYDROXYHEXAHYDROFURO [2, 3-b] FURAN AND RELATED COMPOUNDS |
MY141521A (en) * | 2002-12-12 | 2010-05-14 | Hoffmann La Roche | 5-substituted-six-membered heteroaromatic glucokinase activators |
PL378117A1 (pl) | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tricyklopodstawione związki amidowe |
US7262196B2 (en) | 2003-02-11 | 2007-08-28 | Prosidion Limited | Tri(cyclo) substituted amide glucokinase activator compounds |
EP1598349B1 (en) * | 2003-02-13 | 2011-07-27 | Msd K.K. | Novel 2-pyridinecarboxamide derivatives |
RU2330030C2 (ru) | 2003-02-26 | 2008-07-27 | Баниу Фармасьютикал Ко., Лтд. | Производные гетероарилкарбамоилбензола |
WO2005040142A1 (en) | 2003-10-24 | 2005-05-06 | Aventis Pharmaceuticals Inc. | Novel keto-oxadiazole derivatives as cathepsin inhibitors |
ATE517622T1 (de) | 2003-10-27 | 2011-08-15 | Merck Sharp & Dohme | Salz eines tetrahydropyranylcyclopentyltetrahydropyridopyr diderivats als ccr-2 antagonisten |
MXPA06007667A (es) | 2004-01-06 | 2006-09-01 | Novo Nordisk As | Heteroaril-ureas y su uso como activadores de glucocinasa. |
DE602005013491D1 (de) | 2004-02-18 | 2009-05-07 | Astrazeneca Ab | Benzamidderivate und deren verwendung als glucokinaseaktivierende mittel |
US20080312207A1 (en) | 2004-02-18 | 2008-12-18 | Craig Johnstone | Compounds |
JPWO2005090332A1 (ja) | 2004-03-23 | 2008-01-31 | 萬有製薬株式会社 | 置換キナゾリン又はピリドピリミジン誘導体 |
JP2007530631A (ja) | 2004-04-02 | 2007-11-01 | ノバルティス アクチエンゲゼルシャフト | チアゾロピリジン誘導体、それを含む医薬組成物およびグルコキナーゼ介在性状態の処置法 |
ATE524479T1 (de) | 2004-04-02 | 2011-09-15 | Novartis Ag | Sulfonamidthiazolpyridinderivate als zur behandlung von typ-2-diabetes geeignete glucokinaseaktivatoren |
NZ550567A (en) | 2004-04-21 | 2010-07-30 | Prosidion Ltd | Tri(cyclo) substituted amide compounds |
TW200600086A (en) | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
GB0418046D0 (en) | 2004-08-12 | 2004-09-15 | Prosidion Ltd | Eantioselective process |
MX2007001650A (es) | 2004-08-12 | 2007-07-13 | Prosidion Ltd | Fenilacetamidas substituidas y su uso como activadores de glucocinasa. |
GB0418058D0 (en) | 2004-08-12 | 2004-09-15 | Prosidion Ltd | Fluorination process |
WO2007050087A1 (en) | 2004-08-25 | 2007-05-03 | Ardea Biosciences, Inc. | N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS |
GB0423044D0 (en) | 2004-10-16 | 2004-11-17 | Astrazeneca Ab | Compounds |
BRPI0518798A2 (pt) | 2004-12-03 | 2008-12-09 | Transtech Pharma Inc | composto, composiÇço farmacÊutica, e, mÉtodos para tratar diabete tipo ii e para tratar uma condiÇço ou distérbio |
WO2006064286A1 (en) | 2004-12-13 | 2006-06-22 | Medivir Uk Ltd | Cathepsin s inhibitors |
WO2006094770A2 (en) | 2005-03-08 | 2006-09-14 | Ludwig-Maximilians-Universitaet Muenchen | Apparatus and method for the final processing of a forming tool for a sheet-metal body part |
TW200714597A (en) | 2005-05-27 | 2007-04-16 | Astrazeneca Ab | Chemical compounds |
KR20080024211A (ko) | 2005-07-08 | 2008-03-17 | 노보 노르디스크 에이/에스 | 디시클로알킬 우레아 글루코키나제 활성제 |
JP2009500442A (ja) | 2005-07-09 | 2009-01-08 | アストラゼネカ アクチボラグ | 2型糖尿病を処置するためのグルコキナーゼのモジュレーターとしての2−ヘテロシクリルオキシベンゾイルアミノヘテロシクリル化合物 |
US20080234273A1 (en) | 2005-07-09 | 2008-09-25 | Mckerrecher Darren | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes |
CA2614746C (en) | 2005-07-09 | 2011-05-10 | Astrazeneca Ab | Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes |
RU2420525C2 (ru) | 2005-07-11 | 2011-06-10 | Мицубиси Танабе Фарма Корпорейшн | Производные оксимов и их получение |
AU2006268589B2 (en) | 2005-07-14 | 2011-09-29 | Vtv Therapeutics Llc | Urea glucokinase activators |
JP2009504621A (ja) | 2005-08-09 | 2009-02-05 | アストラゼネカ アクチボラグ | 糖尿病の処置のためのヘテロアリールカルバモイルベンゼン誘導体 |
RU2008112184A (ru) | 2005-08-31 | 2009-10-10 | Астеллас Фарма Инк. (Jp) | Производное тиазола |
GT200600429A (es) | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
GT200600428A (es) | 2005-09-30 | 2007-05-21 | Compuestos organicos | |
EP1960385A1 (en) | 2005-11-01 | 2008-08-27 | Janssen Pharmaceutica N.V. | Substituted dihydroisoindolones as allosteric modulators of glucokinase |
US20080293741A1 (en) | 2005-11-03 | 2008-11-27 | Matthew Colin Thor Fyfe | Tricyclo Substituted Amides as Glucokinase Modulators |
US20090005391A1 (en) | 2005-11-03 | 2009-01-01 | Matthew Colin Thor Fyfe | Tricyclo Substituted Amides |
JP2009514836A (ja) | 2005-11-03 | 2009-04-09 | プロシディオン・リミテッド | トリシクロ置換型アミド |
TWI411607B (zh) | 2005-11-14 | 2013-10-11 | Vitae Pharmaceuticals Inc | 天門冬胺酸蛋白酶抑制劑 |
EP1948614A2 (en) | 2005-11-18 | 2008-07-30 | Takeda San Diego, Inc. | Glucokinase activators |
CA2637172A1 (en) | 2006-01-27 | 2007-08-09 | Array Biopharma Inc. | Pyridin-2-amine derivatives and their use as glucokinase activators |
EP2001875A2 (en) | 2006-03-08 | 2008-12-17 | Takeda San Diego, Inc. | Glucokinase activators |
AU2007235558B2 (en) | 2006-03-24 | 2011-12-01 | Array Biopharma Inc. | 2 -aminopyridine analogs as glucokinase activators |
WO2007115968A2 (en) | 2006-04-12 | 2007-10-18 | F. Hoffmann-La Roche Ag | Process for the preparation of a glucokinase activator |
CA2648852C (en) | 2006-04-20 | 2012-12-11 | Pfizer Products Inc. | Fused phenyl amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases |
WO2007125103A2 (en) | 2006-04-28 | 2007-11-08 | Transtech Pharma, Inc. | Benzamide glucokinase activators |
US7910747B2 (en) | 2006-07-06 | 2011-03-22 | Bristol-Myers Squibb Company | Phosphonate and phosphinate pyrazolylamide glucokinase activators |
US7888504B2 (en) | 2006-07-06 | 2011-02-15 | Bristol-Myers Squibb Company | Glucokinase activators and methods of using same |
WO2008012227A2 (en) | 2006-07-24 | 2008-01-31 | F. Hoffmann-La Roche Ag | Pyrazoles as glucokinase activators |
AU2007276808A1 (en) * | 2006-07-26 | 2008-01-31 | Novartis Ag | Inhibitors of undecaprenyl pyrophosphate synthase |
BRPI0808267A2 (pt) | 2007-03-07 | 2014-07-22 | Kyorin Phamaceutical Co., Ltd | "composto representado pela formula geral (1) ou um sal farmeceuticamente aceitável do mesmo; método para o tratamento ou prevenção de diabetes ; uso do composto; composição farmacêutica e composto representado pela formula geral (3)". |
WO2008132142A2 (en) | 2007-04-27 | 2008-11-06 | Ucb Pharma S.A. | New heterocyclic derivatives useful for the treatment of cns disorders |
CN101121688A (zh) | 2007-09-14 | 2008-02-13 | 南开大学 | 合成奥拉西坦的改进方法 |
-
2009
- 2009-03-09 US US12/400,065 patent/US7741327B2/en active Active
- 2009-04-06 AU AU2009237794A patent/AU2009237794B2/en active Active
- 2009-04-06 SI SI200930274T patent/SI2274297T1/sl unknown
- 2009-04-06 WO PCT/EP2009/054067 patent/WO2009127546A1/en active Application Filing
- 2009-04-06 BR BRPI0911035A patent/BRPI0911035B8/pt active IP Right Grant
- 2009-04-06 ES ES09732665T patent/ES2386192T3/es active Active
- 2009-04-06 CA CA2720524A patent/CA2720524C/en active Active
- 2009-04-06 PT PT09732665T patent/PT2274297E/pt unknown
- 2009-04-06 RU RU2010146384/04A patent/RU2010146384A/ru not_active Application Discontinuation
- 2009-04-06 PL PL09732665T patent/PL2274297T3/pl unknown
- 2009-04-06 DK DK09732665.6T patent/DK2274297T3/da active
- 2009-04-06 AT AT09732665T patent/ATE557017T1/de active
- 2009-04-06 MX MX2010011226A patent/MX2010011226A/es active IP Right Grant
- 2009-04-06 CN CN200980113416.1A patent/CN102007118B/zh active Active
- 2009-04-06 EP EP09732665A patent/EP2274297B1/en active Active
- 2009-04-06 JP JP2011504418A patent/JP5518838B2/ja active Active
- 2009-04-06 KR KR1020107022936A patent/KR101259249B1/ko active IP Right Grant
- 2009-04-13 TW TW098112222A patent/TW200944519A/zh unknown
- 2009-04-14 AR ARP090101306A patent/AR071474A1/es unknown
- 2009-04-14 CL CL2009000889A patent/CL2009000889A1/es unknown
- 2009-04-15 PE PE2009000522A patent/PE20091842A1/es not_active Application Discontinuation
-
2010
- 2010-08-09 IL IL207503A patent/IL207503A/en active IP Right Grant
- 2010-08-27 ZA ZA2010/06159A patent/ZA201006159B/en unknown
-
2012
- 2012-07-13 HR HRP20120589AT patent/HRP20120589T1/hr unknown
- 2012-07-24 CY CY20121100661T patent/CY1112921T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2009000889A1 (es) | Compuestos derivados de 2-oxo-2,5-dihidro pirrol propionamida, activadores de glucoquinasa; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compestos; y su uso en el tratamiento de diabetes mellitus. | |
CL2007002197A1 (es) | Compuestos derivados de indol; procedimiento de preparacion; compuesto intermediario; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes mellitus, retinopatia diabetica, hiperglucemia, hiperl | |
CL2011001497A1 (es) | Compuestos derivados de heterociclos, modulador de gpr120; composicion farmaceutica; y su uso para el tratamiento de diabetes tipo i,ii y sindrome metabolico. | |
CL2011000846A1 (es) | Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c. | |
CL2008002076A1 (es) | Compuestos derivados de ariloxazoles sustituidos; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para tratar diabetes, sindrome metabolico, dislipidemias, entre otras enfermedades. | |
CL2008001271A1 (es) | Compuestos derivados de heterociclos de nitrogeno y oxigeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, hiperglicemia, intolerancia a la glucosa, aterosclerosis, dislipidemia, obesid | |
CL2007001885A1 (es) | Compuestos derivados de urea de tropano, moduladores de la actividad de la 11betahsd1; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como obesidad, diabetes, hipertension, aterosclerosis, demencia y osteoporosis. | |
CL2007002018A1 (es) | Compuestos derivados de isoxazolinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad causada por un aumento en la proliferacion celular. | |
CL2012000921A1 (es) | Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes. | |
CL2008001049A1 (es) | Compuestos derivados de benzamidas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la diabetes, intolerancia a la glucosa, dislipidemia, hipertension, obesidad. | |
CL2011000527A1 (es) | Compuestos derivados de benzofurano; composicion farmaceutica que los comprende;y su uso en el tratamiento de la hepatitis c. | |
CL2009000173A1 (es) | Compuestos derivados de urea-tetrahidroxiquinoxalina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento y la prevencion de la obesidad y la diabetes, resistencia a la insulina, sindrome metabolico, entre otros. | |
DOP2011000176A (es) | Compuestos organicos | |
CL2007002188A1 (es) | Compuestos derivados de heteroarilaminas; procedimiento de preparacion; composicion farmceutica; y uso del compuesto para tratar el crecimiento celular anormal. | |
CL2009000349A1 (es) | Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer. | |
CL2007001869A1 (es) | Compuestos derivados de bencimidazol; procedimiento de preparacion; composiciones farmaceuticas; y uso para el tratamiento y/o profilaxis de enfermedades que se modulan con agonistas del fxr, tal como dislipidemias, diabetes, cancer, osteoporosis y e | |
CL2007003614A1 (es) | Compuestos derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona; composicion farmaceutica que comprende a dicho compuesto; procedimiento de preparacion; y uso del compuesto en el tratamiento de trastornos del metabolismo, como diabetes mellitus, dis | |
CL2007002121A1 (es) | Compuestos derivados de pirazoles, activadores de glucoquinasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que comprende dichos compuestos; y uso para el tratamiento de enfermedades y/o trastornos metabolicos, tal como diab | |
CL2008003116A1 (es) | Compuestos heterocíclicos bicíclicos; composición farmacéutica que comprende a dichos compuestos; y su uso en el tratamiento o prevención de enfermedades tales como diabetes, obesidad, trastorno metabólico, enfermedad cardiovascular entre otras. | |
CL2008001821A1 (es) | Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras. | |
CL2008003847A1 (es) | Compuestos derivados de 6-fenilpirazin-2-carboxamida y 6-fenilpirazin-2-carbotioamida, inhibidores de dgat-1; composicion farmaceutica; y su uso en el tratamiento de la diabetes mellitus y obesidad. | |
CL2012001722A1 (es) | Compuestos derivados de 3-hidroxi-5-arilisotiazol, agonistas del receptor 40 acoplado a la proteina g (gpr40); composición farmacéutica que los comprende; y método para el tratamiento o la prevención de la diabetes. | |
CL2008002295A1 (es) | Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c. | |
CL2007002890A1 (es) | Compuestos derivados de 2-piridincarboxamida, activador de glucosinasa; composicion farmaceutica; y uso del compuesto para el tratamiento de diabetes o la obesidad. | |
CL2007003202A1 (es) | Compuestos derivados de espiroindolinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos de proliferacion celular. |